Company Overview
Percheron Therapeutics Limited (ASX: PER) is a public clinical-stage biotechnology company, focused on the development of novel therapies for rare diseases with high unmet need.
The company’s lead asset is ATL1102, an antisense oligonucleotide therapy targeting VLA4. ATL1102 is currently the subject of an ongoing international Phase IIb clinical trial in Duchenne muscular dystrophy. The drug has shown positive signals of efficacy in a prior Phase IIa study, and has also shown potential efficacy in multiple sclerosis and other indications. ATL1102 has orphan drug designation and rare pediatric disease designation from FDA, and orphan drug designation from EMA. The underlying technology was originally licensed from Ionis Pharmaceuticals (NASDAQ: IONS). The company’s second asset is ATL1103 (atesidorsen), an antisense oligonucleotide against growth hormone receptor, which has completed phase II in acromegaly.
